Clinical studies showed that ESR1 mutations that promote ligand-independent activation (e.g., Y537S, D538G) occur predominantly in metastatic or advanced breast cancer patients who were previously treated with estrogen deprivation therapy, especially aromatase inhibitors. Here, ESR1 is linked to breast cancer.